Literature DB >> 12368071

The participation of galanin in pain processing at the spinal level.

Hong-Xiang Liu1, Tomas Hökfelt.   

Abstract

Galanin, a 29-amino-acid peptide expressed in dorsal root ganglia (DRG) and spinal dorsal horn interneurones, is regulated by nerve injury and peripheral inflammation. The functional significance of such regulation has been subject to intense studies, including the analysis of galanin null mice, with the production of apparently conflicting results. Here, we suggest that upregulation of galanin in DRG neurones following nerve injury results in antinociception via stimulation of galanin GAL1 receptors on dorsal horn neurones, and that the pro-nociceptive effect of galanin is related to presynaptic galanin GAL2 receptors on primary afferents. A selective GAL1 receptor agonist could therefore be valuable for the treatment of neuropathic pain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12368071     DOI: 10.1016/s0165-6147(02)02074-6

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  45 in total

1.  Antinociceptive effects induced by intra-lateral habenula complex injection of the galanin receptor 1 agonist M617 in rats.

Authors:  Li-Bo Fu; Ying Wang; Xiao-Xiao Sun; Xiao-Xia Liu; Ying Wang; Wen Zhuang
Journal:  Exp Brain Res       Date:  2015-11-02       Impact factor: 1.972

2.  Galanin decreases proliferation of PC12 cells and induces apoptosis via its subtype 2 receptor (GalR2).

Authors:  R Tofighi; B Joseph; S Xia; Z-Q D Xu; B Hamberger; T Hökfelt; S Ceccatelli
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-12       Impact factor: 11.205

3.  Phospholipase C{beta}3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain.

Authors:  Tie-Jun Sten Shi; Su-Xing Leslie Liu; Henrik Hammarberg; Masahiko Watanabe; Zhi-Qing David Xu; Tomas Hökfelt
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-09       Impact factor: 11.205

4.  Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues.

Authors:  Liuyin Zhang; Charles R Robertson; Brad R Green; Timothy H Pruess; H Steve White; Grzegorz Bulaj
Journal:  J Med Chem       Date:  2009-03-12       Impact factor: 7.446

5.  Synthesis and biological evaluation of novel pyrimidine derivatives as sub-micromolar affinity ligands of GalR2.

Authors:  Vasudeva Naidu Sagi; Tianyu Liu; Xiaoying Lu; Tamas Bartfai; Edward Roberts
Journal:  Bioorg Med Chem Lett       Date:  2011-09-25       Impact factor: 2.823

Review 6.  Response of substances co-expressed in hypothalamic magnocellular neurons to osmotic challenges in normal and Brattleboro rats.

Authors:  Jana Bundzikova; Zdeno Pirnik; Dora Zelena; Jens D Mikkelsen; Alexander Kiss
Journal:  Cell Mol Neurobiol       Date:  2008-09-05       Impact factor: 5.046

7.  Expression of galanin and galanin receptor mRNA in skin during the formation of granulation tissue.

Authors:  Hiroyuki Yamamoto; Takeo Arai; Shinta Ben; Kazuaki Iguchi; Minoru Hoshino
Journal:  Endocrine       Date:  2011-09-06       Impact factor: 3.633

8.  Postendocytotic traffic of the galanin R1 receptor: a lysosomal signal motif on the cytoplasmic terminus.

Authors:  Sheng Xia; Xing-Peng Dun; Ping-Sheng Hu; Svend Kjaer; Kang Zheng; Yu Qian; Christina Solén; Tao Xu; Bertil Fredholm; Tomas Hökfelt; Zhi-Qing David Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-02       Impact factor: 11.205

9.  Transgenic overexpression of galanin in the dorsal root ganglia modulates pain-related behavior.

Authors:  Fiona E Holmes; Andrea Bacon; Robert J P Pope; Penny A Vanderplank; Niall C H Kerr; Madhu Sukumaran; Vassilis Pachnis; David Wynick
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-29       Impact factor: 11.205

10.  Bidirectional regulation of stress responses by galanin in mice: involvement of galanin receptor subtype 1.

Authors:  K Mitsukawa; X Lu; T Bartfai
Journal:  Neuroscience       Date:  2009-03-09       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.